Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib.

Ripretinib (DCC-2618) is a novel, type II tyrosine switch control inhibitor designed to broadly inhibit activating and drug-resistant mutations in KIT and PDGFRA. Ripretinib has emerged as a promising investigational agent for the treatment of gastrointestinal stromal tumor owing to targeted inhibition of secondary resistance mutations that may develop following treatment with prior line(s) of tyrosine kinase inhibitors. Here we describe the rationale and design of intrigue (NCT03673501), a global, randomized (1:1), open-label, Phase III study comparing the safety and efficacy of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor following imatinib. The primary end point is progression-free survival and key secondary objectives include objective response rate and overall survival. Clinical Trial Registration: NCT03673501.

[1]  M. Heinrich,et al.  INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥ 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753) , 2019, Annals of Oncology.

[2]  Stacie L. Bulfer,et al.  Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. , 2019, Cancer cell.

[3]  M. van de Rijn,et al.  Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs) , 2019, Clinical Sarcoma Research.

[4]  B. Vincenzi,et al.  Secondary KIT mutations: the GIST of drug resistance and sensitivity , 2019, British Journal of Cancer.

[5]  J. Fletcher,et al.  Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours , 2019, British Journal of Cancer.

[6]  M. Heinrich,et al.  Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases. , 2018, Pharmacology & therapeutics.

[7]  O. Rosen,et al.  Initial results of phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  O. Rosen,et al.  Abstract CT029: Pharmacokinetic (PK), safety, and tolerability profile of DCC-2618 in a phase I trial supports 150mg QD selected for a pivotal phase III trial in gastrointestinal stromal tumor (GIST) , 2018, Clinical Trials.

[9]  C. Paweletz,et al.  Phase Ib study of rapid alternation of sunitinib (SU) and regorafenib (RE) in patients (pts) with advanced gastrointestinal stromal tumor (GIST). , 2018 .

[10]  G. Stefanzl,et al.  The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis , 2018, Haematologica.

[11]  A. Le Cesne,et al.  Recent advances in managing gastrointestinal stromal tumor , 2017, F1000Research.

[12]  A. Astolfi,et al.  The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST) , 2017, Journal of Translational Medicine.

[13]  C. Tzen,et al.  A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17 , 2017, Oncotarget.

[14]  S. Sleijfer,et al.  Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Tr , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Stefanzl,et al.  The Multi-Kinase Inhibitor DCC-2618 Inhibits Proliferation and Survival of Neoplastic Mast Cells and Other Cell Types Involved in Systemic Mastocytosis , 2016 .

[16]  J. Fletcher KIT Oncogenic Mutations: Biologic Insights, Therapeutic Advances, and Future Directions. , 2016, Cancer research.

[17]  E. Wardelmann,et al.  Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. Meltzer,et al.  Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. , 2016, JAMA oncology.

[19]  K. Søreide,et al.  Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. , 2016, Cancer epidemiology.

[20]  M. Heinrich,et al.  SDHC methylation in gastrointestinal stromal tumors (GIST): a case report , 2015, BMC Medical Genetics.

[21]  J. Sicklick,et al.  Epidemiology of Gastrointestinal Stromal Tumors in the Era of Histology Codes: Results of a Population-Based Study , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[22]  J. Fletcher,et al.  Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients , 2014, Clinical Cancer Research.

[23]  C. Antonescu,et al.  Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Blay,et al.  Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[25]  Xiaohong Liu,et al.  The expression of KIT receptor dimers in gastrointestinal stromal tumors independent of c-kit mutation and SCF expression is associated with high-risk stratification. , 2012, Oncology letters.

[26]  J. Blay,et al.  Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era , 2012, Clinical Cancer Research.

[27]  Aki Vehtari,et al.  One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. , 2012, JAMA.

[28]  D. Ksienski Imatinib Mesylate: Past Successes and Future Challenges in the Treatment of Gastrointestinal Stromal Tumors , 2011, Clinical Medicine Insights. Oncology.

[29]  J. Lasota,et al.  Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. , 2009, Archives of pathology & laboratory medicine.

[30]  Yan Zhang,et al.  KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients , 2009, Proceedings of the National Academy of Sciences.

[31]  C. Antonescu,et al.  Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  J. Fletcher,et al.  Heterogeneity of kinase inhibitor resistance mechanisms in GIST , 2008, The Journal of pathology.

[33]  C. Antonescu Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas , 2008, Modern Pathology.

[34]  J. Crowley,et al.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  A. Hartmann,et al.  Epithelioid gastric stromal tumours of the antrum in young females with the Carney triad: a report of three new cases with mutational analysis and comparative genomic hybridization. , 2007, Oncology reports.

[36]  J. Fletcher,et al.  KIT mutations in GIST. , 2007, Current opinion in genetics & development.

[37]  Xin Huang,et al.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.

[38]  J. Fletcher,et al.  Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  G. Antoch,et al.  Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib , 2005, International journal of cancer.

[40]  H. Joensuu,et al.  NF1-Associated Gastrointestinal Stromal Tumors Have Unique Clinical, Phenotypic, and Genotypic Characteristics , 2005, The American journal of surgical pathology.

[41]  M. Heinrich,et al.  PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  G. Kanel,et al.  Gastrointestinal stromal tumors: Clinical profile, pathogenesis, treatment strategies and prognosis , 2005, Journal of gastroenterology and hepatology.

[43]  C. Antonescu,et al.  Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation , 2005, Clinical Cancer Research.

[44]  C. Leutner,et al.  Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. , 2005, The Lancet. Oncology.

[45]  P. Marynen,et al.  Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. , 2005, Gastroenterology.

[46]  Rossella Bertulli,et al.  Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial , 2004, The Lancet.

[47]  J. Fletcher,et al.  Biology of gastrointestinal stromal tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  A. D. Van den Abbeele,et al.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Samuel Singer,et al.  PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.

[50]  R. Pazdur,et al.  Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[52]  J. Buckner,et al.  Contrast of Response to Dacarbazine, Mitomycin, Doxorubicin, and Cisplatin (DMAP) Plus GM-CSF Between Patients with Advanced Malignant Gastrointestinal Stromal Tumors and Patients with Other Advanced Leiomyosarcomas , 2002, Cancer investigation.

[53]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[54]  Robin L. Jones,et al.  Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. , 2017, Future oncology.

[55]  B. V. Van Tine,et al.  Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review. , 2017, Journal of gastrointestinal oncology.

[56]  R. Roskoski Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. , 2016, Pharmacological research.

[57]  G. Demetri,et al.  Clinical management of gastrointestinal stromal tumors: before and after STI-571. , 2002, Human pathology.